Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment
ImmunityBio Q3 Adj. EPS $(0.09) Misses $(0.08) Estimate, Sales $48.841M Miss $59.250M Estimate
Loading...